News
Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...
Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, but a win in a head-to-head trial against Novartis’ big-selli
